metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) 5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1
squamous - mNSCLC - L2 - PDL1 positive

All treatments
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib
KRAS gene alteration targeted therapy
sotorasib
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab

versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs docetaxel
vs Standard of Care (SoC)
vs gene alteration target therapy
vs EGFR gene alteration
vs osimertinib
vs non active control
vs no control (uncontrolled study)

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open